Case Report: I want more olanzapine: pharmacogenetic insights into a patient's preference for high-dose olanzapine
Olanzapine is an effective antipsychotic agent, but its metabolism shows considerable interindividual variability. We present a case of a patient with treatment-resistant schizophrenia who consistently required and preferred high-dose olanzapine (40–60 mg/day) for symptom control. The patient report...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1633198/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|